Digital Cognitive Assessments for Early Alzheimer’s Clinical Trials
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
As Alzheimer’s disease (AD) clinical trials are conducted earlier in the disease continuum, efficient approaches to identify appropriate participants are increasingly important. While biomarkers remain essential for confirming underlying AD pathology, large-scale recruitment efforts require practical methods to identify individuals most likely to meet study clinical eligibility criteria.
Digital cognitive assessments offer a scalable and flexible approach to case finding for site- and community-based recruitment settings, as well as for remote use. Real-time scoring, centralized decision-making and remote administration capabilities enable cognitive data to be incorporated into screening workflows, helping researchers identify individuals who are more likely to demonstrate cognitive impairment, be at elevated risk of progression or exhibit biomarker evidence of AD pathology. However, optimal case finding using digital cognitive assessments requires clearly defined and broadly understood decision-making criteria and recommended actions.
This webinar will review key considerations for designing cognitive pre-screening strategies used in clinical trials of preclinical and symptomatic AD. Drawing on examples from clinical trial and observational research, the featured speaker will discuss how digital cognitive assessments can support recruitment efficiency, the characteristics that make cognitive measures suitable for case-finding applications, the conditions necessary for optimal decision making and evidence supporting the use of digital cognitive assessments in participant identification and enrichment strategies.
Register for this webinar to learn how digital cognitive assessments can support effective pre-screening strategies, improve participant identification and enhance recruitment efficiency in early Alzheimer’s disease clinical trials.
Who should attend
- Clinical Development
- Clinical Science
- Neuroscience and Alzheimer’s Disease Research
- Clinical Operations
- Patient Recruitment and Retention
- Clinical Trial Innovation
- Digital Health and Decentralized Trials
- Biomarker and Endpoint Strategy
What you will learn
- Important factors for designing cognitive pre-screening approaches for preclinical and early symptomatic AD clinical trials
- Characteristics of cognitive assessments that make them suitable for case-finding, enrichment and participant triage applications
- How digital cognitive assessments can support identification of individuals with subtle cognitive impairment, elevated risk of future decline and increased likelihood of AD biomarker positivity
- Opportunities and limitations of digital cognitive screening methods to improve recruitment efficiency, accelerate enrollment, reduce screen failures and lower trial timelines and costs
Featured Speaker
Karra Harrington, PhD
Dr. Karra Harrington is a Principal Scientist at Cogstate, where she supports pharma, biotech and healthcare customers with a focus on digital cognitive assessments. She plays a key role in the development and validation of Cogstate’s digital cognitive tests, ensuring they meet the highest scientific and clinical standards. Before joining Cogstate, Karra was an Assistant Research Professor at Penn State. Her research centered on developing smartphone-based cognitive assessments designed to measure cognition remotely and in real-world settings.
Karra holds a PhD in Neuroscience from the University of Melbourne and a Master of Clinical Psychology from Deakin University and is board-endorsed as a Clinical Psychologist in Australia. With over 50 peer-reviewed publications and numerous conference presentations, Karra is a recognized expert in Alzheimer’s disease research and digital cognitive assessment methodologies.
Partner for this event
Cogstate
Cogstate Ltd (ASX:CGS) is a leading science and technology solutions provider dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; elite sporting organizations and military; physicians and patients; renowned academic institutions and public-private partnerships. For more information, please visit www.cogstate.com.